Hall SF, et al. - Researchers identified and quantified risk factors associated with osteoporosis overtreatment in this study. They performed one of the pre-specified post hoc analyses of the Patient Activation After DXA Receipt Notification (PAADRN) trial—a randomized, controlled, pragmatic clinical trial. Among 3,602 patients with no apparent indication for osteoporosis treatment, 292 received a new prescription for osteoporosis pharmacotherapy or were instructed to continue an existing medication (presumed overtreatment). Participants with prior DXA history, those who reported a history of osteoporosis or low bone mass, and those referred for testing by family medicine providers received the presumed overtreatment more commonly. The investigators recommend minimization of overtreatment as it exposes patients to possible risk with negligible chance of benefit.